
About Roopa Industries
Roopa Industries is a publicly listed company based in Hyderabad (India) founded in 2000. Nutraceuticals, bulk drugs, and chemicals are manufactured in Hyderabad. The company has 30 employees. Its Indian entity Roopa Industries Limited reported revenue of βΉ128 Cr. Its focus areas include Diversified Pharmaceuticals.
Company details
Roopa Industries was established in 2000 in Hyderabad, India, within the pharmaceuticals and chemicals sector. Manufacturing operations focus on nutraceuticals such as glucosamine, bulk drugs including esomeprazole magnesium trihydrate and tamsulosin, and chemicals like triphenyl phosphine and bromine derivatives. These products support applications in antibiotics, agrochemicals, dyes, and medical intermediates, with activities centered in the Indian market.
- Headquarters Hyderabad, India
- Employees 30
- Stage Public
- SectorsHealthcare
- Website roopaindustries.com
- Social LinkedIn
- Legal Name Roopa Industries Limited
- Market Cap₹33.59 Cr
ROOPAIND · BSE
- Share Price₹42.25
-1.05% today
- Revenue₹128 Cr
FY 2025-26 · +5.6% YoY
- EBITDA₹4.06 Cr
Margin 3.2%
- Net Profit₹4.17 Cr
FY 2025-26 · +112.8% YoY
- P/E (TTM)8.0x
P/B 1.8x
- ROE23.8%
ROCE 14.9%
- Debt / Equity1.83
Interest cover 98.8x
- Employee Count30
Associated legal entities of Roopa Industries
Roopa Industries operates through Roopa Industries Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Roopa Industries Limited Listed CIN L10100AP1985PLC005582 | Active | 17 Jun 1985 | Kurnool, Andhra Pradesh | ₹128 Cr | 30 | 7 | View details |
Board of directors of Roopa Industries Limited (Roopa Industries)
Roopa Industries Limited is the primary company behind Roopa Industries. The board of Roopa Industries Limited currently have 5 directors; the longest-serving is Joginatha Vaduguri Sarma, appointed in 1999. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Joginatha Vaduguri Sarma DIN 00165204 | Whole-time director | 01 Oct 1999 | 27 yrs 1 mo | Roopa Industries Limited |
| Tumbalam Gooty Raghavendra DIN 00186546 | Managing Director | 01 Oct 2015 | 11 yrs 1 mo | Roopa Industries Limited |
| Karunasree Samudrala DIN 06960974 | Director | 26 Aug 2017 | 9 yrs 2 mo | Roopa Industries Limited |
| Muttaraju Venu Manohar DIN 11272558 | Director | 01 Oct 2025 | 1 yr 1 mo | Roopa Industries Limited |
| Gantla Venkat Reddy DIN 11276913 | Director | 01 Oct 2025 | 1 yr 1 mo | Roopa Industries Limited |
IPO & Listings of Roopa Industries
Roopa Industries is a publicly listed company on the BSE with ticker symbol ROOPAIND in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Aug 1995
- Listed onBSE: 530991
- Listed entityRoopa Industries Limited
- Exchange sectorHealth technology
- ISININE443C01010
- Share price₹47.90 (+5.62% on the day) · 2026-10-14
- Market capitalisation₹35.7 Cr
- Price to earnings294.0
- EPS (diluted, trailing year)₹0.16
- Volume (last session)51
Financials of Roopa Industries
Exchange-reported figures of Roopa Industries Limited, the listed company behind Roopa Industries (BSE: ROOPAIND).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 128 | 121 | 70.43 | 76.17 | 51.21 | 28.61 | 27.65 |
| Revenue growth | +5.6% | +71.4% | -7.5% | +48.7% | +79.0% | +3.5% | - |
| EBITDA | 4.06 | 4.12 | 4.45 | 3.90 | 3.44 | 2.73 | 1.84 |
| EBITDA margin | +3.2% | +3.4% | +6.3% | +5.1% | +6.7% | +9.5% | +6.7% |
| Profit before tax | 0.17 | 2.73 | 2.19 | 1.82 | 1.36 | 0.94 | 0.81 |
| Net profit | 4.17 | 1.96 | 1.46 | 1.37 | 1.01 | 0.72 | 0.38 |
| Net profit margin | +3.3% | +1.6% | +2.1% | +1.8% | +2.0% | +2.5% | +1.4% |
| EPS (βΉ) | 0.11 | 2.59 | 1.93 | 1.72 | 1.29 | 0.91 | 0.47 |
| Balance sheet | |||||||
| Total assets | 49.30 | 51.30 | 41.70 | 33.27 | 24.99 | 25.43 | 24.73 |
| Net worth | 17.60 | 17.50 | 15.48 | 13.95 | 12.59 | 11.57 | 10.80 |
| Total debt | 31.02 | 33.26 | 25.75 | 18.87 | 11.97 | 13.46 | 13.51 |
| Cash & bank | 1.54 | 4.62 | 4.15 | 2.73 | 2.01 | 1.00 | 0.73 |
| Net working capital | 41.31 | 42.94 | 26.54 | 19.71 | 15.13 | 15.55 | 14.76 |
| Cash flow | |||||||
| Cash from operations | 4.68 | (6.59) | 2.01 | (0.37) | 2.34 | (0.52) | 2.44 |
| Cash from investing | (0.49) | 2.18 | 1.11 | (0.99) | 3.65 | 1.34 | 0.70 |
| Cash from financing | (7.50) | 4.82 | (2.09) | 1.81 | (5.01) | (0.58) | (3.06) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.30 | 33.32 | 30.14 | 33.54 | 28.74 | 35.07 | 29.83 | 30.73 |
| Revenue growth (YoY) | +19.4% | -5.0% | +1.0% | +9.1% | +12.2% | +1.6% | - | - |
| Other income | 0.00 | 0.02 | 0.11 | 0.00 | 0.00 | 0.02 | 1.14 | 0.92 |
| Total expenses | 32.63 | 31.80 | 31.16 | 31.51 | 27.11 | 33.67 | 29.39 | 29.76 |
| EBITDA | 1.67 | 1.52 | (1.02) | 2.03 | 1.63 | 1.40 | 0.44 | 0.97 |
| EBITDA margin | +4.9% | +4.6% | -3.4% | +6.1% | +5.7% | +4.0% | +1.5% | +3.2% |
| Depreciation | 0.19 | 0.19 | 0.21 | 0.19 | 0.19 | 0.20 | 0.19 | 0.26 |
| Interest | 1.02 | 0.93 | 0.74 | 0.79 | 0.83 | 0.86 | 0.66 | 0.67 |
| Profit before tax | 0.46 | 0.42 | (1.86) | 1.05 | 0.61 | 0.36 | 0.73 | 0.96 |
| Tax | 0.10 | 0.10 | (0.43) | 0.28 | 0.15 | 0.09 | 0.32 | 0.20 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.30 | 33.32 | 30.14 | 33.54 | 28.74 | 35.07 | 29.83 | 30.73 |
| Revenue growth (YoY) | +19.4% | -5.0% | +1.0% | +9.1% | +12.2% | +1.6% | - | - |
| Other income | 0.00 | 0.02 | 0.11 | 0.00 | 0.00 | 0.02 | 1.14 | 0.92 |
| Total expenses | 32.63 | 31.80 | 31.16 | 31.51 | 27.11 | 33.67 | 29.39 | 29.76 |
| EBITDA | 1.67 | 1.52 | (1.02) | 2.03 | 1.63 | 1.40 | 0.44 | 0.97 |
| EBITDA margin | +4.9% | +4.6% | -3.4% | +6.1% | +5.7% | +4.0% | +1.5% | +3.2% |
| Depreciation | 0.19 | 0.19 | 0.21 | 0.19 | 0.19 | 0.20 | 0.19 | 0.26 |
| Interest | 1.02 | 0.93 | 0.74 | 0.79 | 0.83 | 0.86 | 0.66 | 0.67 |
| Profit before tax | 0.46 | 0.42 | (1.86) | 1.05 | 0.61 | 0.36 | 0.73 | 0.96 |
| Tax | 0.10 | 0.10 | (0.43) | 0.28 | 0.15 | 0.09 | 0.32 | 0.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 128 | 121 | 70.43 | 76.17 | 51.21 | 28.61 | 27.65 |
| Revenue growth | +5.6% | +71.4% | -7.5% | +48.7% | +79.0% | +3.5% | - |
| Other income | 0.13 | 2.30 | 1.13 | 0.65 | 0.06 | 0.08 | 1.09 |
| Total expenses | 123 | 117 | 65.98 | 72.27 | 47.77 | 25.88 | 25.81 |
| Employee cost | 2.93 | 2.83 | 3.47 | 3.24 | 2.21 | 3.77 | 2.36 |
| EBITDA | 4.06 | 4.12 | 4.45 | 3.90 | 3.44 | 2.73 | 1.84 |
| EBITDA margin | +3.2% | +3.4% | +6.3% | +5.1% | +6.7% | +9.5% | +6.7% |
| Depreciation | 0.80 | 0.85 | 0.87 | 0.89 | 0.93 | 0.81 | 0.76 |
| Interest | 3.22 | 2.84 | 2.52 | 1.84 | 1.21 | 1.06 | 1.36 |
| Profit before tax | 0.17 | 2.73 | 2.19 | 1.82 | 1.36 | 0.94 | 0.81 |
| Tax | 0.09 | 0.69 | 0.65 | 0.45 | 0.35 | 0.22 | 0.43 |
| Net profit | 4.17 | 1.96 | 1.46 | 1.37 | 1.01 | 0.72 | 0.38 |
| Net profit margin | +3.3% | +1.6% | +2.1% | +1.8% | +2.0% | +2.5% | +1.4% |
| EPS (βΉ) | 0.11 | 2.59 | 1.93 | 1.72 | 1.29 | 0.91 | 0.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.87 | 7.87 | 7.87 | 7.87 | 7.87 | 7.87 | 7.87 |
| Reserves & surplus | 9.73 | 9.63 | 7.61 | 6.08 | 4.72 | 3.70 | 2.93 |
| Shareholders' funds (net worth) | 17.60 | 17.50 | 15.48 | 13.95 | 12.59 | 11.57 | 10.80 |
| Secured loans | 29.55 | 28.02 | 22.59 | 17.75 | 6.04 | 8.14 | 7.52 |
| Unsecured loans | 1.47 | 5.24 | 3.16 | 1.12 | 5.93 | 5.32 | 5.99 |
| Total debt | 31.02 | 33.26 | 25.75 | 18.87 | 11.97 | 13.46 | 13.51 |
| Total liabilities | 49.30 | 51.30 | 41.70 | 33.27 | 24.99 | 25.43 | 24.73 |
| Assets | |||||||
| Gross block | 18.86 | 17.58 | 18.19 | 19.45 | 18.32 | 18.06 | 17.42 |
| Net block | 8.41 | 7.93 | 8.73 | 9.97 | 9.69 | 10.36 | 10.53 |
| Capital work in progress | 0.00 | 0.88 | 0.88 | 0.88 | 0.69 | 0.10 | 0.00 |
| Investments | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 30.84 | 36.15 | 25.16 | 18.38 | 15.34 | 19.46 | 12.35 |
| Sundry debtors | 21.92 | 13.00 | 8.35 | 7.08 | 15.68 | 11.50 | 11.90 |
| Cash & bank balances | 1.54 | 4.62 | 4.15 | 2.73 | 2.01 | 1.00 | 0.73 |
| Loans & advances | 8.89 | 13.52 | 10.98 | 13.91 | 5.26 | 3.56 | 2.33 |
| Total current assets | 63.19 | 67.29 | 48.64 | 42.10 | 38.29 | 35.52 | 27.31 |
| Total current liabilities | 21.88 | 24.35 | 22.10 | 22.39 | 23.16 | 19.97 | 12.55 |
| Net working capital | 41.31 | 42.94 | 26.54 | 19.71 | 15.13 | 15.55 | 14.76 |
| Total assets | 49.30 | 51.30 | 41.70 | 33.27 | 24.99 | 25.43 | 24.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.38 | 2.98 | 1.95 | 1.49 | 0.50 | 0.26 | 0.17 |
| Net cash from operating activities | 4.68 | (6.59) | 2.01 | (0.37) | 2.34 | (0.52) | 2.44 |
| Net cash from investing activities | (0.49) | 2.18 | 1.11 | (0.99) | 3.65 | 1.34 | 0.70 |
| Net cash from financing activities | (7.50) | 4.82 | (2.09) | 1.81 | (5.01) | (0.58) | (3.06) |
| Net change in cash | (3.31) | 0.40 | 1.03 | 0.45 | 0.99 | 0.25 | 0.08 |
| Closing cash | 1.54 | 4.62 | 4.15 | 2.73 | 2.01 | 1.00 | 0.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.6% | +71.4% | -7.5% | +48.7% | +79.0% | +3.5% | - |
| EBITDA growth | -1.5% | -7.4% | +14.1% | +13.4% | +26.0% | +48.4% | - |
| PBT growth | -93.8% | +24.7% | +20.3% | +33.8% | +44.7% | +16.1% | +1.3% |
| Net income growth | +112.8% | +34.3% | +6.6% | +35.6% | +40.3% | +89.5% | - |
| Revenue CAGR (3Y) | +18.7% | +33.1% | +35.0% | +40.2% | +19.3% | +14.7% | -2.7% |
| EBITDA CAGR (3Y) | +1.4% | +6.2% | +17.7% | +28.5% | +11.1% | - | -6.4% |
| Profitability & leverage | |||||||
| Net income margin | +0.1% | +1.7% | +2.2% | +1.8% | +2.0% | +2.5% | +1.4% |
| Return on capital employed | +14.9% | +12.0% | +12.5% | +12.5% | +10.2% | +8.0% | +8.5% |
| Return on net worth | +23.8% | +12.3% | +10.3% | +10.2% | +8.4% | +6.4% | +3.5% |
| Debt / equity | 1.83 | 1.79 | 1.52 | 1.16 | 1.05 | 1.21 | 1.35 |
| Long-term debt / equity | 0.27 | 0.37 | 0.24 | 0.16 | 0.37 | 0.53 | 0.63 |
| Interest cover | 98.77 | 86.85 | 70.39 | 61.13 | 48.21 | 55.21 | 125.93 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 7.00 | 6.75 | 3.74 | 4.03 | 2.82 | 1.61 | 1.85 |
| Inventory turnover | 3.81 | 3.94 | 3.24 | 4.52 | 2.94 | 1.80 | 2.40 |
| Debtors turnover | 7.30 | 11.31 | 9.13 | 6.69 | 3.77 | 2.45 | 2.41 |
| EPS (βΉ) | 0.11 | 2.59 | 1.93 | 1.72 | 1.29 | 0.91 | 0.47 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 22.37 | 22.24 | 19.67 | 17.73 | 16.00 | 14.70 | 13.73 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Roopa Industries
Complete news archive for Roopa Industries
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Roopa Industries
Roopa Industries was founded in 2000.
Roopa Industries is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Roopa Industries has 30 employees.
The primary company behind Roopa Industries, Roopa Industries Limited, reported revenue of βΉ128 Cr for FY 2026, up 6% year on year.
Roopa Industries was established in 2000 in Hyderabad, India, within the pharmaceuticals and chemicals sector. Manufacturing operations focus on nutraceuticals such as glucosamine, bulk drugs including esomeprazole magnesium trihydrate and tamsulosin, and chemicals like triphenyl phosphine and bromine derivatives. These products support applications in antibiotics, agrochemicals, dyes, and medical intermediates, with activities centered in the Indian market.
Yes, Roopa Industries is publicly traded on BSE under the ticker symbol ROOPAIND.
Roopa Industries operates through Roopa Industries Limited.
The legal entities of Roopa Industries currently have 7 directors, including Karunasree Samudrala, Joginatha Vaduguri Sarma, Tumbalam Gooty Raghavendra and others.
